These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2681442)

  • 61. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
    Chung YH; Shong YK
    Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Natural autoantibodies to interferons.
    Meager A
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S51-3. PubMed ID: 9241617
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation.
    Prümmer O; Bunjes D; Wiesneth M; Hertenstein B; Arnold R; Porzsolt F; Heimpel H
    Bone Marrow Transplant; 1996 Apr; 17(4):617-23. PubMed ID: 8722365
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical significance of recombinant interferon-alpha 2 neutralizing antibodies in hepatitis patients.
    Antonelli G; Giannelli G; Pistello M; Maggi F; Vatteroni L; Currenti M; Del Vecchio S; Roffi L; Pastore G; Dianzani F
    J Interferon Res; 1994 Aug; 14(4):211-3. PubMed ID: 7822878
    [No Abstract]   [Full Text] [Related]  

  • 65. Production of subtype-specific antipeptide antibodies to human interferon-alpha 1 and -alpha 4.
    Sattayasai N; Hibbs AR; McMullen GL; Linnane AW; Marzuki S
    J Interferon Res; 1988 Jun; 8(3):325-32. PubMed ID: 3411162
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A radioimmunologic technique to screen for antibodies to alpha-2 interferon.
    Protzman WP; Jacobs SL; Minnicozzi M; Oden EM; Kelsey DK
    J Immunol Methods; 1984 Dec; 75(2):317-23. PubMed ID: 6097611
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alpha interferon in the treatment of chronic myelomonocytic leukemia.
    Catalano L; Majolino I; Musto P; Fragrasso A; Molica S; Cirincione S; Selleri C; Luciano L; De Renzo A; Vecchione R
    Haematologica; 1989; 74(6):577-81. PubMed ID: 2628240
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patients treated with natural (leukocyte-derived) interferon (IFN)-alpha do not develop IFN antibodies.
    Osterborg A; Engman K; Björeman M; Carlson K; Kimby E; Ohrling M; Samuelsson J; Osby E; Mellstedt H
    Eur J Haematol; 1991 Sep; 47(3):234-5. PubMed ID: 1915808
    [No Abstract]   [Full Text] [Related]  

  • 69. A sensitive radioimmunoassay for detection of antibodies to recombinant human interferon-alpha A.
    Palleroni AV; Trown PW
    J Interferon Res; 1986 Dec; 6(6):705-12. PubMed ID: 3572089
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b.
    von Wussow P; Hartmann F; Freund M; Poliwoda H; Deicher H
    Lancet; 1988 Apr; 1(8590):882-3. PubMed ID: 2895387
    [No Abstract]   [Full Text] [Related]  

  • 71. Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumor-associated antigen in human breast cancer cells.
    Iacobelli S; Scambia G; Natoli C; Panici PB; Baiocchi G; Perrone L; Mancuso S
    Int J Cancer; 1988 Aug; 42(2):182-4. PubMed ID: 3403063
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients.
    Steinmann GG; Göd B; Rosenkaimer F; Adolf G; Bidlingmaier G; Frühbeis B; Lamche H; Lindner J; Patzelt E; Schmähling C
    Clin Investig; 1992 Feb; 70(2):136-41. PubMed ID: 1600338
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.
    Hansen MB; Svenson M; Bendtzen K
    Clin Exp Immunol; 1992 Jun; 88(3):559-62. PubMed ID: 1606741
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Perspectives on the neutralization of interferons by antibody.
    Grossberg SE
    Neurology; 2003 Nov; 61(9 Suppl 5):S21-3. PubMed ID: 14610106
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunogenicity of recombinant human proteins: causes and consequences.
    Schellekens H; Casadevall N
    J Neurol; 2004 Jun; 251 Suppl 2():II4-9. PubMed ID: 15264106
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The detection of antibodies to recombinant interferon alfa-2a in human serum.
    Hennes U; Jucker W; Fischer EA; Krummenacher T; Palleroni AV; Trown PW; Linder-Ciccolunghi S; Rainisio M
    J Biol Stand; 1987 Jul; 15(3):231-44. PubMed ID: 3301856
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Are all type I human interferons equivalent?
    Foster GR; Finter NB
    J Viral Hepat; 1998 May; 5(3):143-52. PubMed ID: 9658366
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Production and characterization of thirteen human type-I interferon-α subtypes.
    Kuruganti S; Accavitti-Loper MA; Walter MR
    Protein Expr Purif; 2014 Nov; 103():75-83. PubMed ID: 25149396
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.
    Silver RT; Vandris K
    Leukemia; 2009 Jul; 23(7):1366-9. PubMed ID: 19440212
    [No Abstract]   [Full Text] [Related]  

  • 80. Specificities of therapy-induced anti-interferon-alpha antibodies.
    Brand CM; Leadbeater L
    J Interferon Res; 1994 Aug; 14(4):201-3. PubMed ID: 7822875
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.